BACKGROUND: Anemia is a factor that affects the outcome of patients with chronic kidney disease (CKD); however, there are only a few reports on the management of anemia in Japanese patients with CKD who are not on dialysis. METHODS: We investigated the prevalence, related factors and management of anemia in CKD stage 3-5 patients in Japan based on the baseline data obtained from a prospective cohort study (Chronic Kidney Disease Japan Cohort). Anemia was defined as having a hemoglobin (Hb) level of <11 g/dL or receiving erythropoiesis stimulating agent (ESA) therapy. RESULTS: The result indicated that 946 out of 2,930 patients had anemia. Of these 946 patients, 385 were receiving ESA treatment for anemia and had an Hb level of 10.28 ± 1.19 g/dL (mean ± SD). The percentage of these patients with an Hb level above the target of 11 g/dL proposed for treatment by the Japanese guidelines, and above the maintenance level of 10 g/dL approved for ESA therapy in Japan, was only 30.1 and 61.6%, respectively. In contrast, the percentage of patients receiving no ESA therapy was 67.6 and 55.7%, respectively, among those with an Hb level of <11 and <10 g/dL. CONCLUSIONS: These data suggested that prevalence of anemia was high in Japanese patients with CKD stage 3-5, that the percentage of patients receiving ESA was low among those who required ESA, and that a large number of patients receiving ESA failed to maintain the recommended level of Hb.
BACKGROUND:Anemia is a factor that affects the outcome of patients with chronic kidney disease (CKD); however, there are only a few reports on the management of anemia in Japanese patients with CKD who are not on dialysis. METHODS: We investigated the prevalence, related factors and management of anemia in CKD stage 3-5 patients in Japan based on the baseline data obtained from a prospective cohort study (Chronic Kidney Disease Japan Cohort). Anemia was defined as having a hemoglobin (Hb) level of <11 g/dL or receiving erythropoiesis stimulating agent (ESA) therapy. RESULTS: The result indicated that 946 out of 2,930 patients had anemia. Of these 946 patients, 385 were receiving ESA treatment for anemia and had an Hb level of 10.28 ± 1.19 g/dL (mean ± SD). The percentage of these patients with an Hb level above the target of 11 g/dL proposed for treatment by the Japanese guidelines, and above the maintenance level of 10 g/dL approved for ESA therapy in Japan, was only 30.1 and 61.6%, respectively. In contrast, the percentage of patients receiving no ESA therapy was 67.6 and 55.7%, respectively, among those with an Hb level of <11 and <10 g/dL. CONCLUSIONS: These data suggested that prevalence of anemia was high in Japanese patients with CKD stage 3-5, that the percentage of patients receiving ESA was low among those who required ESA, and that a large number of patients receiving ESA failed to maintain the recommended level of Hb.
Authors: Francesco Locatelli; Pedro Aljama; Peter Bárány; Bernard Canaud; Fernando Carrera; Kai-Uwe Eckardt; Walter H Hörl; Iain C Macdougal; Alison Macleod; Andrzej Wiecek; Stewart Cameron Journal: Nephrol Dial Transplant Date: 2004-05 Impact factor: 5.992
Authors: D S Silverberg; D Wexler; D Sheps; M Blum; G Keren; R Baruch; D Schwartz; T Yachnin; S Steinbruch; I Shapira; S Laniado; A Iaina Journal: J Am Coll Cardiol Date: 2001-06-01 Impact factor: 24.094
Authors: Panagiotis T Vlagopoulos; Hocine Tighiouart; Daniel E Weiner; John Griffith; Dan Pettitt; Deeb N Salem; Andrew S Levey; Mark J Sarnak Journal: J Am Soc Nephrol Date: 2005-09-14 Impact factor: 10.121
Authors: A Al-Ahmad; W M Rand; G Manjunath; M A Konstam; D N Salem; A S Levey; M J Sarnak Journal: J Am Coll Cardiol Date: 2001-10 Impact factor: 24.094
Authors: Jai Radhakrishnan; Giuseppe Remuzzi; Rajiv Saran; Desmond E Williams; Nilka Rios-Burrows; Neil Powe; Katharina Brück; Christoph Wanner; Vianda S Stel; Sree K Venuthurupalli; Wendy E Hoy; Helen G Healy; Anne Salisbury; Robert G Fassett; Donal O'Donoghue; Paul Roderick; Seiichi Matsuo; Akira Hishida; Enyu Imai; Satoshi Iimuro Journal: Kidney Int Date: 2014-06-04 Impact factor: 10.612
Authors: José Portolés; Jose Luis Gorriz; Esther Rubio; Fernando de Alvaro; Florencio García; Vicente Alvarez-Chivas; Pedro Aranda; Alberto Martinez-Castelao Journal: BMC Nephrol Date: 2013-01-07 Impact factor: 2.388